靶向治疗联合同步放化疗对局部晚期非小细胞肺癌患者临床疗效及安全性的临床研究

洪娟 杨(河北省沧州中西医结合医院放化疗科，中国)
文博 杨(河北省沧州中西医结合医院放化疗科，中国)
月红 孙(河北省沧州中西医结合医院放化疗科，中国)
建西 周(河北省沧州中西医结合医院放化疗科，中国)
云川 孙(河北省沧州中西医结合医院放化疗科，中国)

摘要

目的本研究通过比较不可手术切除的局部晚期非小细胞肺癌靶向治疗联合同步放化疗与同步放化疗的临床疗效及安全性，为临床治疗提供依据。方法本研究收集我院2020年6月~2021年6月符合入组标准的局部晚期非小细胞肺癌患者，共有102例符合条件的患者入组，吉非替尼+同步放化疗组及同步放化疗组各51例。比较两组患者的临床疗效、肿瘤复发率、中位无进展时间、总生存时间及不良反应发生情况。结果：吉非替尼+同步放化疗组CR 6例（11.8%），PR 23例（45.1%），SD 16例（31.4%），PD 6例（11.7%）。同步放化疗组CR 1例（2.0%），PR 15例（29.4%），SD 22例（43.1%），PD 13例（25.5%）。吉非替尼联合同步放化疗组与同步放化疗组的DCR分别为88.2%（47/51）、74.5%（38/51），差异具有统计学差异（X2值为5.718，P＜0.05）。两组的肿瘤局部复发率分别为15.7%（8/51）、33.3%（17/51），差异具有统计学差异（X2值为4.292，P＜0.05。中位PFS分别为 14.0个月（95%置信区间为11.6 -16.4）、8.9个月（95%置信区间为8.4 -9.4），两组差异有统计学意义（P＜0.05）。中位OS分别为40.1个月（95%置信区间为32.9 -47.3）、28.4个月（95%置信区间为25.4 -31.3），两组间差异有统计学意义（P＜0.05）。两组无严重不良反应发生，吉非替尼联合同步放化疗组皮疹的发生率较高，但安全可控。结论: 吉非替尼靶向治疗联合同步放化疗可提高不可切除III期非小细胞肺癌患者的局部控制率，提高PFS及OS，安全可控。

关键词

靶向治疗；同步放化疗；局部晚期非小细胞肺癌；无进展生存时间；总生存时间；不良反应

参考

Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41(10):1037‐1048.

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta‐analysis of concomitant versus sequential radiochemotherapy in locally advanced non‐small‐cell lung cancer. J Clin Oncol. 2010;28(13):2181‐2190.

Huber RM, De Ruysscher D, Hoffmann H, Reu S, Tufman A. Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev. 2019;28(152):190024.

Akamatsu H, Murakami H, Harada H, Shimizu J, Hayashi H, Daga H, et al. Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. J Thorac Oncol. 2021;16(10):1745‐1752.

Xing L, Wu G, Wang L, Li J‐C, Wang J, Yuan Z, et al. A multicenter, randomized, open‐label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. Journal of Clinical Oncology. 2017;35(15 suppl):8531.

Bi N, Xu K, Ge H, Chen M, Mingyan E, Zhang L, et al. Real‐world treatment patterns and clinical outcomes in EGFR‐mutant locally advanced lung adenocarcinoma: A multi‐center cohort study. Journal of the National Cancer Center. 2023;3(1):65‐71.

Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181-90.

Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(7): 706-714.

Naidoo J, Antonia SJ, Wu Y‐L, et al. Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation‐positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC. Journal of Clinical Oncology. 2022; 40(16 suppl):8541.

Shi L, Tang J, Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2014; 83(2):231-9.

Jia W, Guo H, Jing W, et al. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. Radiother Oncol. 2020; 152:96-100.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v9i2.36552